GLP-1s, Urolithin A & Urolithin B: Uncovering the Mitochondria-Metabolism-Brain Axis

Could metabolic aging, chronic anxiety, and depression all share the same biological root? In this episode of The Energy Code, Dr. Mike Belkowski reviews three newly published studies that, when viewed together, point toward an emerging concept he calls the mitochondria-metabolism-brain axis. The first paper explores how GLP-1 medications may influence mitochondrial biology beyond weight loss by interacting with pathways involved in mitochondrial biogenesis, oxidative stress, and cellular resilience. The second investigates how Urolithin A restored mitophagy and eliminated anxiety-like behavior in animal models. The third demonstrates how Urolithin B improved depression-like behavior by activating mitochondrial quality-control pathways through SLP2 and the PINK1/Parkin signaling system. While much of the evidence remains preclinical, the convergence across these independent research groups is striking. Rather than focusing on three different diseases, the episode explores one shared biological thread: mitochondrial quality control. If these findings continue to translate into humans, they could fundamentally reshape how we think about metabolism, aging, inflammation, resilience, and brain health. (Educational content only, not medical advice.) - Articles Discussed in Episode: The GLP-1–Mitochondria Axis in Metabolic Aging Urolithin A Abolishes High Anxiety and Rescues the Associated Mitochondria-Related Transcriptomic Signatures and Synaptic Function Urolithin B Ameliorates Depressive-Like Behavior and Hippocampal Neuronal Damage in Depressed Rats via Regulation of the SLP2/PINK1/Parkin Signaling Pathway - Key Quotes From Dr. Mike: "The real question isn't whether one of these compounds works — it's whether we're uncovering a broader mitochondria-metabolism-brain axis." "Mitochondrial dysfunction sits at the center of metabolic aging." "GLP-1 drugs may be touching the exact mitochondrial machinery that declines with age." "Urolithin A didn't simply reduce anxiety — it appeared to restore the mitochondrial quality control system underlying it." "Urolithin B improved behavior, protected hippocampal neurons, and reduced neuroinflammation." "Mitochondrial quality control may be one of the shared nodes connecting metabolism, aging, inflammation, and the brain." "The mitochondrion is beginning to look less like a power plant and more like a resilience hub." - Key Points ⚡ Three newly published studies explored metabolic aging, anxiety, and depression—but all converged on mitochondrial biology as a shared mechanism. ⚡ The episode introduces the emerging concept of the mitochondria-metabolism-brain axis. ⚡ A new Aging Cell review proposes that mitochondrial dysfunction sits at the center of metabolic aging. ⚡ Age-related declines in NAD, sirtuins, PGC-1α, mitochondrial biogenesis, and mitophagy may collectively drive metabolic decline. ⚡ GLP-1 receptor agonists may influence mitochondrial function through AMPK, PGC-1α, NRF2, and mitophagy pathways. ⚡ Despite compelling mechanisms, direct mitochondrial benefits of GLP-1 drugs in humans remain an active hypothesis—not established fact. ⚡ Large clinical trials continue to demonstrate significant cardiovascular and metabolic benefits from GLP-1 therapies. ⚡ Neurons have extraordinarily high energy demands, making the brain especially vulnerable to mitochondrial dysfunction. ⚡ A new Biological Psychiatry study found that Urolithin A eliminated anxiety-like behavior in multiple rodent models. ⚡ Urolithin A restored mitochondrial quality control by improving mitophagy through the PINK1/Parkin pathway. ⚡ The anti-anxiety effects occurred without sedation and primarily benefited animals exhibiting high anxiety. ⚡ Urolithin A also restored neuronal connectivity, dendritic complexity, synaptic function, and Mitofusin-2 expression. ⚡ A second study found that Urolithin B significantly improved depression-like behavior in stressed rats. ⚡ Urolithin B reduced neuroinflammation, preserved hippocampal neurons,